Nonprescription drugs : over the counter and underemphasized : report to the Chairman, Subcommittee on Regulation, Business Opportunities, and Energy, Committee on Small Business, House of Representatives /

Drug control : Treatment Alternatives Program for drug offenders needs stronger emphasis : report to the Chairman, Select Committee on Narcotics Abuse and Control, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Select Committee on Narcotics Abuse and Control.

"February 1993.""B-252082"--P. 1."GAO/GGD-93-61."Cover title.Includes bibliographical references.Mod...

FDA drug review : postapproval risks, 1976-85 : report to the Chairman, Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Operations, House of Representatives.

United States. General Accounting Office.

"B-235944"--P. [1]"GAO/PEMD-90-15.""April 1990."Cover title.Includes bibliographical references (p. ...

Impact of clandestine drug laboratories on small business : hearing before the Subcommittee on Regulation and Business Opportunities of the Committee on Small Business, House of Representatives, One Hundredth Congress, second session, Eugene, OR, May 13, 1988.

United States. Congress. House. Committee on Small Business. Subcommittee on Regulation and Business Opportunities.

January 1988

"Serial no. 100-50."Includes bibliographical references.Mode of access: Internet

Nonprescription drugs : value of a pharmacist-controlled class has yet to be demonstrated : report to the Ranking Minority Member, Committee on Commerce, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Committee on Commerce.

"B-252141"--P. [1]."GAO/PEMD-95-12.""August 1995."Cover title.Includes bibliographical references (p...

Off-label drugs : reimbursement policies constrain physicians in their choice of cancer therapies : report to the Chairman, Committee on Labor and Human Resources, House of Representatives /

United States. General Accounting Office.
United States. Congress. Senate. Committee on Labor and Human Resources.

"B-242851"--P. [1]."GAO/PEMD-91-14.""September 1991."Cover title.Mode of access: Internet

Off-label drug use and FDA review of supplemental drug applications : hearing before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, second session, September 12, 1996.

United States. Congress. House. Committee on Government Reform and Oversight. Subcommittee on Human Resources and Intergovernmental Relations.

January 1997

Shipping list no.: 97-0120-P.Distributed to some depository libraries in microfiche.Includes bibliog...

Nonprescription Drugs: Considerations Regarding a Behind-the-Counter Drug Class

United States. Government Accountability Office.

February 2009

A letter report issued by the Government Accountability Office with an abstract that begins "In the ...

NONPRESCRIPTION DRUG REGULATION IN THE UNITED STATES

Debra Bowen Md

October 2016

In the United States, nonprescription drug products are regulated through implementation of laws ena...

Promotion of drugs and medical devices for unapproved uses : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, first session, June 11, 1991.

United States. Congress. House. Committee on Government Operations. Human Resources and Intergovernmental Relations Subcommittee.

January 1992

Shipping list no.: 92-273-P.Distributed to some depository libraries in microfiche.Includes bibliogr...

Drug control : status report on counterdrug technology development : report to Congressional requesters /

United States. General Accounting Office.

Cover title."B-242554"--P. 1."GAO/NSIAD-93-104.""January 1993."Mode of access: Internet

Questionable sales practices in the drug industry : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, second session, Washington, DC, October 12, 1994.

United States. Congress. House. Committee on Small Business. Subcommittee on Regulation, Business Opportunities, and Technology.

January 1995

"Serial no. 103-107."Shipping list no.: 95-0084-P.Distributed to some depository libraries in microf...

Regulation of over-the-counter drugs [microform] : hearing before the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, first session, June 22, 1979.

United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Oversight and Investigations.

Reuse of record except for individual research requires license from Congressional Information Servi...

Drug control : oversight needed to prevent acquisition of unnecessary equipment : report to the Chairman, Committee on Government Operations, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Committee on Government Operations.

"B-242554"--P. 1."July 1992."Cover title."GAO/NSIAD-92-260."Mode of access: Internet

Drug treatment : some clinics not meeting goal of prompt treatment for intravenous drug users.

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment.
United States. General Accounting Office.

January 1990

"April 1990.""GAO/HRD-90-80BR."At head of title: United States General Accounting Office, briefing r...

Prescription drug monitoring : states can readily identify illegal sales and use of controlled substances : report to the Chairman, Subcommittee on Health, Committee on Ways and Means, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Committee on Ways and Means. Subcommittee on Health.

"GAO/HRD-92-115.""B-248618"--P. 1.Cover title."July 1992."Includes bibliographical references.Mode o...

Drug control : Treatment Alternatives Program for drug offenders needs stronger emphasis : report to the Chairman, Select Committee on Narcotics Abuse and Control, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Select Committee on Narcotics Abuse and Control.

"February 1993.""B-252082"--P. 1."GAO/GGD-93-61."Cover title.Includes bibliographical references.Mod...

FDA drug review : postapproval risks, 1976-85 : report to the Chairman, Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Operations, House of Representatives.

United States. General Accounting Office.

"B-235944"--P. [1]"GAO/PEMD-90-15.""April 1990."Cover title.Includes bibliographical references (p. ...

Impact of clandestine drug laboratories on small business : hearing before the Subcommittee on Regulation and Business Opportunities of the Committee on Small Business, House of Representatives, One Hundredth Congress, second session, Eugene, OR, May 13, 1988.

United States. Congress. House. Committee on Small Business. Subcommittee on Regulation and Business Opportunities.

January 1988

"Serial no. 100-50."Includes bibliographical references.Mode of access: Internet

Nonprescription drugs : value of a pharmacist-controlled class has yet to be demonstrated : report to the Ranking Minority Member, Committee on Commerce, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Committee on Commerce.

"B-252141"--P. [1]."GAO/PEMD-95-12.""August 1995."Cover title.Includes bibliographical references (p...

Off-label drugs : reimbursement policies constrain physicians in their choice of cancer therapies : report to the Chairman, Committee on Labor and Human Resources, House of Representatives /

United States. General Accounting Office.
United States. Congress. Senate. Committee on Labor and Human Resources.

"B-242851"--P. [1]."GAO/PEMD-91-14.""September 1991."Cover title.Mode of access: Internet

Off-label drug use and FDA review of supplemental drug applications : hearing before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, second session, September 12, 1996.

United States. Congress. House. Committee on Government Reform and Oversight. Subcommittee on Human Resources and Intergovernmental Relations.

January 1997

Shipping list no.: 97-0120-P.Distributed to some depository libraries in microfiche.Includes bibliog...

Nonprescription Drugs: Considerations Regarding a Behind-the-Counter Drug Class

United States. Government Accountability Office.

February 2009

A letter report issued by the Government Accountability Office with an abstract that begins "In the ...

NONPRESCRIPTION DRUG REGULATION IN THE UNITED STATES

Debra Bowen Md

October 2016

In the United States, nonprescription drug products are regulated through implementation of laws ena...

Promotion of drugs and medical devices for unapproved uses : hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, first session, June 11, 1991.

United States. Congress. House. Committee on Government Operations. Human Resources and Intergovernmental Relations Subcommittee.

January 1992

Shipping list no.: 92-273-P.Distributed to some depository libraries in microfiche.Includes bibliogr...

Drug control : status report on counterdrug technology development : report to Congressional requesters /

United States. General Accounting Office.

Cover title."B-242554"--P. 1."GAO/NSIAD-93-104.""January 1993."Mode of access: Internet

Questionable sales practices in the drug industry : hearing before the Subcommittee on Regulation, Business Opportunities, and Technology of the Committee on Small Business, House of Representatives, One Hundred Third Congress, second session, Washington, DC, October 12, 1994.

United States. Congress. House. Committee on Small Business. Subcommittee on Regulation, Business Opportunities, and Technology.

January 1995

"Serial no. 103-107."Shipping list no.: 95-0084-P.Distributed to some depository libraries in microf...

Regulation of over-the-counter drugs [microform] : hearing before the Subcommittee on Oversight and Investigations of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-sixth Congress, first session, June 22, 1979.

United States. Congress. House. Committee on Interstate and Foreign Commerce. Subcommittee on Oversight and Investigations.

Reuse of record except for individual research requires license from Congressional Information Servi...

Drug control : oversight needed to prevent acquisition of unnecessary equipment : report to the Chairman, Committee on Government Operations, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Committee on Government Operations.

"B-242554"--P. 1."July 1992."Cover title."GAO/NSIAD-92-260."Mode of access: Internet

Drug treatment : some clinics not meeting goal of prompt treatment for intravenous drug users.

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment.
United States. General Accounting Office.

January 1990

"April 1990.""GAO/HRD-90-80BR."At head of title: United States General Accounting Office, briefing r...

Prescription drug monitoring : states can readily identify illegal sales and use of controlled substances : report to the Chairman, Subcommittee on Health, Committee on Ways and Means, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Committee on Ways and Means. Subcommittee on Health.

"GAO/HRD-92-115.""B-248618"--P. 1.Cover title."July 1992."Includes bibliographical references.Mode o...

Drug control : Treatment Alternatives Program for drug offenders needs stronger emphasis : report to the Chairman, Select Committee on Narcotics Abuse and Control, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Select Committee on Narcotics Abuse and Control.

"February 1993.""B-252082"--P. 1."GAO/GGD-93-61."Cover title.Includes bibliographical references.Mod...

FDA drug review : postapproval risks, 1976-85 : report to the Chairman, Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Operations, House of Representatives.

United States. General Accounting Office.

"B-235944"--P. [1]"GAO/PEMD-90-15.""April 1990."Cover title.Includes bibliographical references (p. ...

Impact of clandestine drug laboratories on small business : hearing before the Subcommittee on Regulation and Business Opportunities of the Committee on Small Business, House of Representatives, One Hundredth Congress, second session, Eugene, OR, May 13, 1988.

United States. Congress. House. Committee on Small Business. Subcommittee on Regulation and Business Opportunities.

January 1988

"Serial no. 100-50."Includes bibliographical references.Mode of access: Internet

Nonprescription drugs : over the counter and underemphasized : report to the Chairman, Subcommittee on Regulation, Business Opportunities, and Energy, Committee on Small Business, House of Representatives /

Abstract

Extracted data

Nonprescription drugs : over the counter and underemphasized : report to the Chairman, Subcommittee on Regulation, Business Opportunities, and Energy, Committee on Small Business, House of Representatives /

Abstract

Extracted data

Related items

Related items